Respiratory
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
Big pharma once again fails to dominate the top 20 expected best sellers from products due for launch this year. Small-to-medium pharma account for nearly half the list, while Vertex has two products in the top five.
Only two drugs have been approved for the progressive fibrosing interstitial lung disease but the pipeline is full of promising, and hopefully more tolerable, candidates.
The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.
As the architect of the company’s hugely successful business model, Stuart Arbuckle, departs, he hands over a portfolio expanding beyond its cystic fibrosis base, but one that might be slow to build revenues for Casgevy and Journavx.
The PDE4B inhibitor showed improvement in lung function in patients with progressive pulmonary fibrosis in a second positive Phase III trial in pulmonary fibrosis.
The US company has voluntarily halted enrolment in BEACON-IPF of bexotegrast on the recommendation of the trial’s independent data safety monitoring board, leaving analysts puzzled over the drug's prospects for the lung disease.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
The CEO has trumpeted the UK giant’s pipeline and potential growth as it aims for £40bn of sales in six years’ time.
The Japanese pharma firm has sued a politician claiming defamatory actions on social media around its novel COVID-19 vaccine.
The UK biotech has a potential blockbuster on its hands with Ohtuvayre and its strong sales showing so soon after launch could led to a lucrative licensing deal or possible takeover.
While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.
Vertex hopes to convert CF patients to new combo Alyftrek from Trikafta with once-daily dosing. Approved on 20 December, the new triplet has longer patent protection and 7% higher US pricing.
The company’s deupirfenidone, a selectively deuterated version of Roche's Esbriet, has bested the original in a Phase IIb trial in idiopathic pulmonary fibrosis patients. Now, PureTech can finalize the Phase III program and decide how to finance it.
The Lexington, MA-based firm lost three quarters of its value after it voluntarily halted dosing in two arms of a Phase II trial of its lead product, cibotercept, on safety concerns. Some observers think the reaction was overblown, however.
Verona Pharma is rising high with the newly-launched chronic obstructive pulmonary disease drug Ohtuvayre but its development would have been severely compromised if it had not been for government benefits, non-executive chair David Ebsworth tells Scrip.
The second podcast in our series marking 20 years of the Scrip Awards and their recognition of biopharma innovation looking back at some of the trends that have shaped the sector in that time.
AstraZeneca and Amgen’s first-in-class anti-TSLP agent Tezspire, already approved for severe asthma, has shown an ability to reduce the size of nasal polyps and improve congestion.
Sales of its novel COPD therapy in its first quarter on the market were more than double consensus estimates, and Verona sees more to come.
The UK group began more clinical trials last year than any other company, a new report from Citeline has found.